<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02427126</url>
  </required_header>
  <id_info>
    <org_study_id>2014-005109-19</org_study_id>
    <nct_id>NCT02427126</nct_id>
  </id_info>
  <brief_title>Apixaban for Treatment of Embolic Stroke of Undetermined Source</brief_title>
  <acronym>ATTICUS</acronym>
  <official_title>Apixaban for Treatment of Embolic Stroke of Undetermined Source (ATTICUS Randomized Trial)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital Tuebingen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital Tuebingen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Multicentre (national, Germany), randomized (2x2 factorial), open, parallel group, active
      controlled, efficacy study (phase III)
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Based on the previous data, ATTICUS is designed as multicentre, national, parallel group,
      active controlled, phase III randomized (2x2 factorial), clinical trial to demonstrate the
      superiority of apixaban against the current standard of treatment (acetylsalicylic acid) for
      the longterm treatment after ESUS. ATTICUS will follow a dynamic treatment protocol
      implementing conversion from the acetylsalicylic acid arm to the apixaban arm in case of
      detection of relevant episodes of AF during the course of the study. ATTICUS is designed to
      test the superiority over acetylsalicylic acid to reduce new ischemic lesion detected by
      FLAIR/DWI MRI.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2015</start_date>
  <completion_date type="Anticipated">December 2023</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Imaging Endpoint: Occurrence of at least one new ischemic lesion at 12 months after study drug initiation when compared to baseline MRI before study drug initiation</measure>
    <time_frame>12 months</time_frame>
    <description>The primary endpoint will be the occurrence of at least one new ischemic lesion identified by magnetic resonance imaging (axial T2-weighted fluid attenuated inversion recovery MRI (FLAIR) and/or axial diffusion weighted MRI (DWI)) at 12 months when compared to the baseline MRI (FLAIR, DWI) obtained at the time of study drug initiation. MRI at 12 months will be directly compared with the baseline MRI to assess for new ischemic lesions.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Combination of recurrent ischaemic stroke, hemorrhagic stroke, systemic embolism</measure>
    <time_frame>12 months</time_frame>
    <description>The occurence of ischaemic stroke, hemorrhagic stroke, or systemic embolism during study participation (12months) will be quantified</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Combination of major adverse cardiovascular events (MACE) including recurrent stroke, myocardial infarction and cardiovascular death</measure>
    <time_frame>12 months</time_frame>
    <description>The occurence of major adverse cardiovascular events (MACE) including recurrent stroke, myocardial infarction and cardiovascular death during study participation (12months) will be quantified</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Combination of major and clinically relevant non-major bleedings defined according to ISTH criteria</measure>
    <time_frame>12 months</time_frame>
    <description>The occurence of major and clinically relevant non-major bleedings defined according to ISTH criteria during study participation (12months) will be quantified</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of cognitive function (MOCA)</measure>
    <time_frame>12 months</time_frame>
    <description>MOCA test will be performed upon study enrollment and 12 months after enrollment and both tests will be compared</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Life quality (EQ-5D)</measure>
    <time_frame>12 months</time_frame>
    <description>EQ-5D questionnaire will be raised upon study enrollment and 12 months after enrollment and both questionnaires will be compared</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Embolic Stroke of Undetermined Source</condition>
  <arm_group>
    <arm_group_label>Apixaban</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Apixaban 5mg b.i.d. Study treatment: 12 months Follow-up: 30 days after last study drug intake</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Aspirin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Acetylic Salicylic Acid 100mg o.d.; Study treatment: 12 months Follow-up: 30 days after last study drug intake</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Apixaban</intervention_name>
    <description>Apixaban is an oral anticoagulant currently approved for prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation, for the treatment of deep vein thrombosis and pulmonary embolism, and for the prophylaxis of systemic embolism after orthopedic surgery</description>
    <arm_group_label>Apixaban</arm_group_label>
    <other_name>Eliquis</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aspirin</intervention_name>
    <description>Acetylic Salicylic Acid 100mg o.d.; 12 Months</description>
    <arm_group_label>Aspirin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria Must be ≥ 18 years at the time of signing the informed consent.

          -  ESUS must be defined according to following criteria:

               -  Stroke detected by CT or MRI that is not lacunar

               -  Absence of extracranial or intracranial atherosclerosis causing ≥50% luminal
                  stenosis in arteries supplying the area of ischaemia

               -  No major-risk cardioembolic source of embolism

               -  No other specific cause of stroke identified

          -  * At least one of the following non-major but suggestive risk factors for cardiac
             embolism:

               -  LA size &gt;45mm (parasternal axis)

               -  spontaneous echo contrast in LAA

               -  LAA flow velocity &lt;=0.2m/s

               -  atrial high rate episodes

               -  CHA2DS2-Vasc score &gt;=4

               -  persistent foramen ovale

          -  Understand and voluntarily sign an informed consent document

          -  Women of childbearing potential (WOCBP) must be using an adequate method of
             contraception.

        Exclusion Criteria:

          -  History of hypersensitivity to the investigational medicinal product

          -  Participation in other clinical trials or observation period of competing trials.

          -  Arteria cerebri media stroke affecting &gt; 30% of c o r r e s p o n d i n g territory

          -  Diagnosis of haemorrhage or other pathology,

          -  Clear indication for anticoagulation

          -  Inability to control following risk factors for Hemorrhagic Transformation of fresh
             cerebral Infarction (HTI) during index hospital stay: presence of HTI at the time of
             anticoagulation, blood pressure &gt;140 mmHg systolic, abnormal blood glucose Clear
             indication for dual antiplatelet therapy

          -  Clear stroke-/non-stroke-indication for concomitant long-term therapy with
             antiplatelets (e.g. acetylsalicylic acid (ASA), Clopidogrel, or Prasugrel) or with
             non-steroidal anti-inflammatory drugs (NSAID).

          -  Concomitant systemic therapy with strong inhibitors of cytochrome P450 3A4 (CYP3A4)
             and P-glycoprotein (P-gp), i.e. azole antimycotics and human immunodeficiency virus
             (HIV)-protease inhibitors.

          -  Contraindication to investigational medications

          -  Planned or likely therapy with fibrinolytic agents within 48 hours of first study
             medication

          -  History of intracranial, intraocular, spinal, retroperitoneal or atraumatic
             intra-articular bleeding

          -  Gastrointestinal bleed or major surgery within 3 months

          -  Planned or likely revascularization (any angioplasty or vascular surgery) within the
             next 3 months

          -  TIA or minor stroke induced by angiography or surgery

          -  Severe non-cardiovascular comorbidity with life expectancy &lt; 3 months

          -  Severe renal failure, defined as Glomerular Filtration Rate (GFR) &lt;15ml/min

          -  Severe hepatic insufficiency (Child-Pugh score B to C),

          -  Active liver disease,

          -  Contraindications against performance of MRI (pacemaker/ICD), previous implantation
             non-MRI capable protheses

          -  Patients considered unreliable by the investigator, or having a life expectancy less
             than the expected duration of the trial
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tobias Geisler, Prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>Tübingen University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Tobias Geisler, Prof</last_name>
    <phone>0049 ( 0) 7071 29 87320</phone>
    <email>tobias.geisler@med.uni-tuebingen.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sven Poli, Prof</last_name>
    <phone>0049 ( 0) 7071 29 82049</phone>
    <email>sven.poli@uni-tuebingen.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>MedicalPark Berlin Humboldtmühle GmbH &amp; Co. KG</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Klinik für NeurologieKnappschaftskrankenhaus Bochum-Langendreer</name>
      <address>
        <city>Bochum</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Neurologische Klinik, Universität Bonn</name>
      <address>
        <city>Bonn</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Felix Bode, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Regiomed Kliniken Coburg GmbH Abt. II</name>
      <address>
        <city>Coburg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Johannes Brachmann, Prof</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Neurologie, Klinikum Friedrichshafen GmbH</name>
      <address>
        <city>Friedrichshafen</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Roman Huber, Prof</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsmedizin Göttingen Abt.Innere Medizin, Klinik für Kardiologie und Pneumologie,</name>
      <address>
        <city>Göttingen</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jan Liman, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Krankenhaus Martha-Maria Halle-Döhlau</name>
      <address>
        <city>Halle</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrea Kraft, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Klinik für Neurolgie,UKSH Campus Kiel</name>
      <address>
        <city>Kiel</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Klinik für Neurologie, Klinikum Ludwigsburg</name>
      <address>
        <city>Ludwigsburg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitätsklinik für Neurologie, Magdeburg</name>
      <address>
        <city>Magdeburg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Görtler, Prof.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Carl von Basedow KlinikumSaalekreis gGmbH</name>
      <address>
        <city>Merseburg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carsten Hobohm, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Johannes Wesling Kliniken</name>
      <address>
        <city>Minden</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Peter Schellinger, Prof.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinkum Münster, Stroke Unit</name>
      <address>
        <city>Münster</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Rainer Dziewas, Prof.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Marienhospital Stuttgart, Klinik für Neurologie</name>
      <address>
        <city>Stuttgart</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alfred Lindner, Prof</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Neurologische Klinik des Bürgerhospitals</name>
      <address>
        <city>Stuttgart</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marc Etienne Wolf, Dr. med.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital</name>
      <address>
        <city>Tubingen</city>
        <zip>D72076</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tobias Geisler, Prof</last_name>
    </contact>
    <contact_backup>
      <last_name>Timea Keller, Mrs</last_name>
    </contact_backup>
    <investigator>
      <last_name>Tobias Geisler, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sven Poli, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jürgen Schreieck, PD Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitäts- und Rehabilitationskliniken Ulm,Klinik für Neurologie</name>
      <address>
        <city>Ulm</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Katharina Althaus, Dr</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Schwarzwald Baar Klinikum GmbH</name>
      <address>
        <city>Villingen-Schwenningen</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Werner Jung, Prof</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Rems-Murr-Klinikum WinnendenNeurologie</name>
      <address>
        <city>Winnenden</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fabian Hillenbrand, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>May 2019</verification_date>
  <study_first_submitted>March 20, 2015</study_first_submitted>
  <study_first_submitted_qc>April 24, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 27, 2015</study_first_posted>
  <last_update_submitted>July 19, 2019</last_update_submitted>
  <last_update_submitted_qc>July 19, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 23, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ESUS</keyword>
  <keyword>anticoagulation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspirin</mesh_term>
    <mesh_term>Apixaban</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

